Effect of Chronic Endometritis on Prognosis and Reproductive Outcomes in Infertile Women With Endometrial Hyperplasia
American Journal of Reproductive Immunology · 2025
DOI: 10.1111/aji.70075 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Reproductive Immunology, 2025. Verfasst von Xiaotong Dong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Endometritis, Endometrial Hyperplasia, Infertility, Female, Endometrium. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Key R&D Program of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Problem Chronic endometritis has been shown to cause infertility, and chronic inflammation has been confirmed to be associated with the development of cancer. However, the effect of chronic endometritis on endometrial hyperplasia (EH) among infertile women has not been studied. So, we aim to investigate whether chronic endometritis affects the prognosis and reproductive outcome in infertile women with EH who had preserved fertility therapy.
Method
This study employed a retrospective design. Infertile women who underwent hysteroscopic biopsy and were diagnosed as EH were enrolled. We used CD138 immunohistochemical staining in endometrium paraffin sections of EH patients. The patients were divided into two groups according to whether they were diagnosed as chronic endometritis or not, and the disease outcome and reproductive outcome were analyzed.
Result
The results showed that after progesterone therapy, women with a persistent chronic endometritis exhibited a lower rate of complete response ( p = 0.002) of EH, along with an increased incidence of miscarriage after embryo transfer ( p = 0.005).
Conclusion
Our study indicates a high prevalence rate of chronic endometritis in infertile women with EH, with potential implications for prognosis and subsequent reproductive outcomes, whether antibiotics should be added to the treatment of patients with EH combined with chronic endometritis deserves further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Integration and Practice Center, Cheeloo College of Medicine, Shandong University, Jinan, China.
- State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Institute of Women, Children and Reproductive Health, Shandong University, Jinan, China.
- National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Shandong University, Jinan, Shandong, China.
- Key laboratory of Reproductive Endocrinology (Shandong University), Ministry of Education, Jinan, Shandong, China.
- Shandong Technology Innovation Center for Reproductive Health, Jinan, Shandong, China.
- Shandong Provincial Clinical Research Center for Reproductive Health, Jinan, Shandong, China.
ORCID-Profile: Lei Yan
Förderung
- National Key R&D Program of China
- National Key Research and Development Program of China
Zitieren
APA
Dong, X., Zhang, Y., Liu, S., Du, Y., Cui, L., Liu, W., & Yan, L. (2025). Effect of Chronic Endometritis on Prognosis and Reproductive Outcomes in Infertile Women With Endometrial Hyperplasia. American Journal of Reproductive Immunology. https://doi.org/10.1111/aji.70075
Vancouver
Dong X, Zhang Y, Liu S, Du Y, Cui L, Liu W, et al. Effect of Chronic Endometritis on Prognosis and Reproductive Outcomes in Infertile Women With Endometrial Hyperplasia. American Journal of Reproductive Immunology. 2025. doi:10.1111/aji.70075
BibTeX
@article{Dong2025,
author = {Dong, Xiaotong and Zhang, Yang and Liu, Shuai and Du, Yanbo and Cui, Linlin and Liu, Wen and Yan, Lei},
title = {Effect of Chronic Endometritis on Prognosis and Reproductive Outcomes in Infertile Women With Endometrial Hyperplasia},
journal = {American Journal of Reproductive Immunology},
year = {2025},
doi = {10.1111/aji.70075}
}
EUVIMED